within Pharmacolibrary.Drugs.ATC.J;

model J04BA50
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 1.3333333333333333e-05,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J04BA50</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Dapsone and rifampicin are antibacterial drugs used in combination as part of multidrug therapy for the treatment of leprosy (Hansen's disease). Dapsone is a sulfone antibiotic with bacteriostatic effects, while rifampicin is a rifamycin antibiotic with potent bactericidal action against Mycobacterium leprae. This combination remains standard of care for leprosy and is still in use today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for typical adult patients (sex unspecified) treated for leprosy, as PK data on the fixed combination are not directly available in the literature; parameters based on monotherapy data for dapsone and rifampicin.</p><h4>References</h4><ol><li><p>Venkatesan, K (1989). Clinical pharmacokinetic considerations in the treatment of patients with leprosy. <i>Clinical pharmacokinetics</i> 16(6) 365–386. DOI:<a href=\"https://doi.org/10.2165/00003088-198916060-00003\">10.2165/00003088-198916060-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2661102/\">https://pubmed.ncbi.nlm.nih.gov/2661102</a></p></li><li><p>Zilly, W, et al., &amp; Richter, E (1977). Pharmacokinetic interactions with rifampicin. <i>Clinical pharmacokinetics</i> 2(1) 61–70. DOI:<a href=\"https://doi.org/10.2165/00003088-197702010-00005\">10.2165/00003088-197702010-00005</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/140033/\">https://pubmed.ncbi.nlm.nih.gov/140033</a></p></li><li><p>Holdiness, MR (1989). Clinical pharmacokinetics of clofazimine. A review. <i>Clinical pharmacokinetics</i> 16(2) 74–85. DOI:<a href=\"https://doi.org/10.2165/00003088-198916020-00002\">10.2165/00003088-198916020-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2656045/\">https://pubmed.ncbi.nlm.nih.gov/2656045</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J04BA50;
